The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer
Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Since clinical benefits are limited to a subset of patients, we aimed to identify peripheral blood biomarkers that predict the efficacy of the anti-programmed cell death protein 1 (PD-1) antibody (nivolumab) in pati...
Gespeichert in:
| Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2023-01, Vol.72 (1), p.169-181 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 181 |
|---|---|
| container_issue | 1 |
| container_start_page | 169 |
| container_title | Cancer Immunology, Immunotherapy |
| container_volume | 72 |
| creator | Nose, Yohei Saito, Takuro Yamamoto, Kei Yamashita, Kotaro Tanaka, Koji Yamamoto, Kazuyoshi Makino, Tomoki Takahashi, Tsuyoshi Kawashima, Atsunari Haruna, Miya Hirata, Michinari Ueyama, Azumi Iwahori, Kota Satoh, Taroh Kurokawa, Yukinori Eguchi, Hidetoshi Doki, Yuichiro Wada, Hisashi |
| description | Background
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Since clinical benefits are limited to a subset of patients, we aimed to identify peripheral blood biomarkers that predict the efficacy of the anti-programmed cell death protein 1 (PD-1) antibody (nivolumab) in patients with gastric cancer.
Methods
We collected peripheral blood samples from gastric cancer patients (
n
= 29) before and after treatment with nivolumab and investigated the relationship between the frequency of surface or intracellular markers among nivolumab-binding PD-1
+
CD8
+
T cells and treatment responses using multicolor flow cytometry. The tumors, lymph nodes, and peripheral blood of gastric cancer patients who underwent gastrectomy following nivolumab treatment were collected, and nivolumab-binding PD-1
+
CD8
+
T cells in these tissue samples were characterized.
Results
Patients with a high frequency of CD103 among PD-1
+
CD8
+
T cells in peripheral blood 2 weeks after the start of treatment had significantly better progression-free survival than the low group (
P
= 0.032). This CD103
+
PD-1
+
CD8
+
T cell population mainly consisted of central memory T cells, showing the high expression of Ki-67 and few cytotoxic granules. In contrast, effector memory T cells were more frequently observed among CD103
+
PD-1
+
CD8
+
T cells in tumors, which implied a change in the differentiated status of central memory T cells in lymph nodes and peripheral blood to effector memory T cells in tumors during the treatment with ICIs.
Conclusions
A high frequency of CD103 among PD-1
+
CD8
+
T cells 2 weeks after nivolumab treatment in patients with advanced gastric cancer may be a useful biomarker for predicting the efficacy of anti-PD-1 therapy. |
| doi_str_mv | 10.1007/s00262-022-03240-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10991138</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2760705826</sourcerecordid><originalsourceid>FETCH-LOGICAL-c530t-29c698773239308abfff3186d1b0db4c34260b06e8a31dac0f60a7a2a82f0c053</originalsourceid><addsrcrecordid>eNp9UcFu1DAUtBCIbgs_wAFZ4tJL6LOd2M4JoS0FpEpwWM6W4zi7Llk7-CWV-vd42VKgBw6W7fdmxm88hLxi8JYBqAsE4JJXwMsSvIaKPyErVoty1Q17SlYgSlEB1CfkFPGmHDi07XNyIhqlJJOwIrebnadzQFx8lT2G3seZ7m3-7jNdXzIQNEU6-Rymnc92pN2YUk831PlxRDpl3wc3Iy3UKUX0SOdEbZxD9fWyYnQ-kKY7GiLdWpxzcNTZ6Hx-QZ4NdkT_8n4_I9-uPmzWn6rrLx8_r99fV64RMFe8dbLVSgkuWgHadsMwCKZlzzrou9qJmkvoQHptBeutg0GCVZZbzQdw0Igz8u6oOy3d3veuuCsuzJRD8Xhnkg3m304MO7NNt4aVj2JM6KJwfq-Q04_F42z2AQ_ubfRpQcOlrqFVHGSBvnkEvUlLjsWf4UqCgkbzA4ofUS4nxOyHh2kYmEOu5pirKbmaX7kaXkiv__bxQPkdZAGIIwBLK259_vP2f2R_ArOtrcM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2760705826</pqid></control><display><type>article</type><title>The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer</title><source>MEDLINE</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Nose, Yohei ; Saito, Takuro ; Yamamoto, Kei ; Yamashita, Kotaro ; Tanaka, Koji ; Yamamoto, Kazuyoshi ; Makino, Tomoki ; Takahashi, Tsuyoshi ; Kawashima, Atsunari ; Haruna, Miya ; Hirata, Michinari ; Ueyama, Azumi ; Iwahori, Kota ; Satoh, Taroh ; Kurokawa, Yukinori ; Eguchi, Hidetoshi ; Doki, Yuichiro ; Wada, Hisashi</creator><creatorcontrib>Nose, Yohei ; Saito, Takuro ; Yamamoto, Kei ; Yamashita, Kotaro ; Tanaka, Koji ; Yamamoto, Kazuyoshi ; Makino, Tomoki ; Takahashi, Tsuyoshi ; Kawashima, Atsunari ; Haruna, Miya ; Hirata, Michinari ; Ueyama, Azumi ; Iwahori, Kota ; Satoh, Taroh ; Kurokawa, Yukinori ; Eguchi, Hidetoshi ; Doki, Yuichiro ; Wada, Hisashi</creatorcontrib><description>Background
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Since clinical benefits are limited to a subset of patients, we aimed to identify peripheral blood biomarkers that predict the efficacy of the anti-programmed cell death protein 1 (PD-1) antibody (nivolumab) in patients with gastric cancer.
Methods
We collected peripheral blood samples from gastric cancer patients (
n
= 29) before and after treatment with nivolumab and investigated the relationship between the frequency of surface or intracellular markers among nivolumab-binding PD-1
+
CD8
+
T cells and treatment responses using multicolor flow cytometry. The tumors, lymph nodes, and peripheral blood of gastric cancer patients who underwent gastrectomy following nivolumab treatment were collected, and nivolumab-binding PD-1
+
CD8
+
T cells in these tissue samples were characterized.
Results
Patients with a high frequency of CD103 among PD-1
+
CD8
+
T cells in peripheral blood 2 weeks after the start of treatment had significantly better progression-free survival than the low group (
P
= 0.032). This CD103
+
PD-1
+
CD8
+
T cell population mainly consisted of central memory T cells, showing the high expression of Ki-67 and few cytotoxic granules. In contrast, effector memory T cells were more frequently observed among CD103
+
PD-1
+
CD8
+
T cells in tumors, which implied a change in the differentiated status of central memory T cells in lymph nodes and peripheral blood to effector memory T cells in tumors during the treatment with ICIs.
Conclusions
A high frequency of CD103 among PD-1
+
CD8
+
T cells 2 weeks after nivolumab treatment in patients with advanced gastric cancer may be a useful biomarker for predicting the efficacy of anti-PD-1 therapy.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-022-03240-2</identifier><identifier>PMID: 35776160</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Apoptosis ; Biomarkers ; Biomarkers - metabolism ; Cancer Research ; CD103 antigen ; CD8 antigen ; CD8-Positive T-Lymphocytes ; Cell death ; Cytotoxicity ; Effector cells ; Flow cytometry ; Gastrectomy ; Gastric cancer ; Humans ; Immune checkpoint inhibitors ; Immunological memory ; Immunology ; Immunotherapy ; Lymph nodes ; Lymphatic system ; Lymphocytes ; Lymphocytes T ; Medicine ; Medicine & Public Health ; Memory cells ; Monoclonal antibodies ; Nivolumab - pharmacology ; Nivolumab - therapeutic use ; Oncology ; Original ; Original Article ; Patients ; PD-1 protein ; Peripheral blood ; Progression-Free Survival ; Stomach Neoplasms - pathology ; Targeted cancer therapy ; Tumors</subject><ispartof>Cancer Immunology, Immunotherapy, 2023-01, Vol.72 (1), p.169-181</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c530t-29c698773239308abfff3186d1b0db4c34260b06e8a31dac0f60a7a2a82f0c053</citedby><cites>FETCH-LOGICAL-c530t-29c698773239308abfff3186d1b0db4c34260b06e8a31dac0f60a7a2a82f0c053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10991138/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10991138/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35776160$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nose, Yohei</creatorcontrib><creatorcontrib>Saito, Takuro</creatorcontrib><creatorcontrib>Yamamoto, Kei</creatorcontrib><creatorcontrib>Yamashita, Kotaro</creatorcontrib><creatorcontrib>Tanaka, Koji</creatorcontrib><creatorcontrib>Yamamoto, Kazuyoshi</creatorcontrib><creatorcontrib>Makino, Tomoki</creatorcontrib><creatorcontrib>Takahashi, Tsuyoshi</creatorcontrib><creatorcontrib>Kawashima, Atsunari</creatorcontrib><creatorcontrib>Haruna, Miya</creatorcontrib><creatorcontrib>Hirata, Michinari</creatorcontrib><creatorcontrib>Ueyama, Azumi</creatorcontrib><creatorcontrib>Iwahori, Kota</creatorcontrib><creatorcontrib>Satoh, Taroh</creatorcontrib><creatorcontrib>Kurokawa, Yukinori</creatorcontrib><creatorcontrib>Eguchi, Hidetoshi</creatorcontrib><creatorcontrib>Doki, Yuichiro</creatorcontrib><creatorcontrib>Wada, Hisashi</creatorcontrib><title>The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>Background
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Since clinical benefits are limited to a subset of patients, we aimed to identify peripheral blood biomarkers that predict the efficacy of the anti-programmed cell death protein 1 (PD-1) antibody (nivolumab) in patients with gastric cancer.
Methods
We collected peripheral blood samples from gastric cancer patients (
n
= 29) before and after treatment with nivolumab and investigated the relationship between the frequency of surface or intracellular markers among nivolumab-binding PD-1
+
CD8
+
T cells and treatment responses using multicolor flow cytometry. The tumors, lymph nodes, and peripheral blood of gastric cancer patients who underwent gastrectomy following nivolumab treatment were collected, and nivolumab-binding PD-1
+
CD8
+
T cells in these tissue samples were characterized.
Results
Patients with a high frequency of CD103 among PD-1
+
CD8
+
T cells in peripheral blood 2 weeks after the start of treatment had significantly better progression-free survival than the low group (
P
= 0.032). This CD103
+
PD-1
+
CD8
+
T cell population mainly consisted of central memory T cells, showing the high expression of Ki-67 and few cytotoxic granules. In contrast, effector memory T cells were more frequently observed among CD103
+
PD-1
+
CD8
+
T cells in tumors, which implied a change in the differentiated status of central memory T cells in lymph nodes and peripheral blood to effector memory T cells in tumors during the treatment with ICIs.
Conclusions
A high frequency of CD103 among PD-1
+
CD8
+
T cells 2 weeks after nivolumab treatment in patients with advanced gastric cancer may be a useful biomarker for predicting the efficacy of anti-PD-1 therapy.</description><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Biomarkers - metabolism</subject><subject>Cancer Research</subject><subject>CD103 antigen</subject><subject>CD8 antigen</subject><subject>CD8-Positive T-Lymphocytes</subject><subject>Cell death</subject><subject>Cytotoxicity</subject><subject>Effector cells</subject><subject>Flow cytometry</subject><subject>Gastrectomy</subject><subject>Gastric cancer</subject><subject>Humans</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunological memory</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Lymph nodes</subject><subject>Lymphatic system</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Memory cells</subject><subject>Monoclonal antibodies</subject><subject>Nivolumab - pharmacology</subject><subject>Nivolumab - therapeutic use</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>Peripheral blood</subject><subject>Progression-Free Survival</subject><subject>Stomach Neoplasms - pathology</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9UcFu1DAUtBCIbgs_wAFZ4tJL6LOd2M4JoS0FpEpwWM6W4zi7Llk7-CWV-vd42VKgBw6W7fdmxm88hLxi8JYBqAsE4JJXwMsSvIaKPyErVoty1Q17SlYgSlEB1CfkFPGmHDi07XNyIhqlJJOwIrebnadzQFx8lT2G3seZ7m3-7jNdXzIQNEU6-Rymnc92pN2YUk831PlxRDpl3wc3Iy3UKUX0SOdEbZxD9fWyYnQ-kKY7GiLdWpxzcNTZ6Hx-QZ4NdkT_8n4_I9-uPmzWn6rrLx8_r99fV64RMFe8dbLVSgkuWgHadsMwCKZlzzrou9qJmkvoQHptBeutg0GCVZZbzQdw0Igz8u6oOy3d3veuuCsuzJRD8Xhnkg3m304MO7NNt4aVj2JM6KJwfq-Q04_F42z2AQ_ubfRpQcOlrqFVHGSBvnkEvUlLjsWf4UqCgkbzA4ofUS4nxOyHh2kYmEOu5pirKbmaX7kaXkiv__bxQPkdZAGIIwBLK259_vP2f2R_ArOtrcM</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Nose, Yohei</creator><creator>Saito, Takuro</creator><creator>Yamamoto, Kei</creator><creator>Yamashita, Kotaro</creator><creator>Tanaka, Koji</creator><creator>Yamamoto, Kazuyoshi</creator><creator>Makino, Tomoki</creator><creator>Takahashi, Tsuyoshi</creator><creator>Kawashima, Atsunari</creator><creator>Haruna, Miya</creator><creator>Hirata, Michinari</creator><creator>Ueyama, Azumi</creator><creator>Iwahori, Kota</creator><creator>Satoh, Taroh</creator><creator>Kurokawa, Yukinori</creator><creator>Eguchi, Hidetoshi</creator><creator>Doki, Yuichiro</creator><creator>Wada, Hisashi</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230101</creationdate><title>The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer</title><author>Nose, Yohei ; Saito, Takuro ; Yamamoto, Kei ; Yamashita, Kotaro ; Tanaka, Koji ; Yamamoto, Kazuyoshi ; Makino, Tomoki ; Takahashi, Tsuyoshi ; Kawashima, Atsunari ; Haruna, Miya ; Hirata, Michinari ; Ueyama, Azumi ; Iwahori, Kota ; Satoh, Taroh ; Kurokawa, Yukinori ; Eguchi, Hidetoshi ; Doki, Yuichiro ; Wada, Hisashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c530t-29c698773239308abfff3186d1b0db4c34260b06e8a31dac0f60a7a2a82f0c053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Biomarkers - metabolism</topic><topic>Cancer Research</topic><topic>CD103 antigen</topic><topic>CD8 antigen</topic><topic>CD8-Positive T-Lymphocytes</topic><topic>Cell death</topic><topic>Cytotoxicity</topic><topic>Effector cells</topic><topic>Flow cytometry</topic><topic>Gastrectomy</topic><topic>Gastric cancer</topic><topic>Humans</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunological memory</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Lymph nodes</topic><topic>Lymphatic system</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Memory cells</topic><topic>Monoclonal antibodies</topic><topic>Nivolumab - pharmacology</topic><topic>Nivolumab - therapeutic use</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>Peripheral blood</topic><topic>Progression-Free Survival</topic><topic>Stomach Neoplasms - pathology</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nose, Yohei</creatorcontrib><creatorcontrib>Saito, Takuro</creatorcontrib><creatorcontrib>Yamamoto, Kei</creatorcontrib><creatorcontrib>Yamashita, Kotaro</creatorcontrib><creatorcontrib>Tanaka, Koji</creatorcontrib><creatorcontrib>Yamamoto, Kazuyoshi</creatorcontrib><creatorcontrib>Makino, Tomoki</creatorcontrib><creatorcontrib>Takahashi, Tsuyoshi</creatorcontrib><creatorcontrib>Kawashima, Atsunari</creatorcontrib><creatorcontrib>Haruna, Miya</creatorcontrib><creatorcontrib>Hirata, Michinari</creatorcontrib><creatorcontrib>Ueyama, Azumi</creatorcontrib><creatorcontrib>Iwahori, Kota</creatorcontrib><creatorcontrib>Satoh, Taroh</creatorcontrib><creatorcontrib>Kurokawa, Yukinori</creatorcontrib><creatorcontrib>Eguchi, Hidetoshi</creatorcontrib><creatorcontrib>Doki, Yuichiro</creatorcontrib><creatorcontrib>Wada, Hisashi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nose, Yohei</au><au>Saito, Takuro</au><au>Yamamoto, Kei</au><au>Yamashita, Kotaro</au><au>Tanaka, Koji</au><au>Yamamoto, Kazuyoshi</au><au>Makino, Tomoki</au><au>Takahashi, Tsuyoshi</au><au>Kawashima, Atsunari</au><au>Haruna, Miya</au><au>Hirata, Michinari</au><au>Ueyama, Azumi</au><au>Iwahori, Kota</au><au>Satoh, Taroh</au><au>Kurokawa, Yukinori</au><au>Eguchi, Hidetoshi</au><au>Doki, Yuichiro</au><au>Wada, Hisashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>72</volume><issue>1</issue><spage>169</spage><epage>181</epage><pages>169-181</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>Background
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Since clinical benefits are limited to a subset of patients, we aimed to identify peripheral blood biomarkers that predict the efficacy of the anti-programmed cell death protein 1 (PD-1) antibody (nivolumab) in patients with gastric cancer.
Methods
We collected peripheral blood samples from gastric cancer patients (
n
= 29) before and after treatment with nivolumab and investigated the relationship between the frequency of surface or intracellular markers among nivolumab-binding PD-1
+
CD8
+
T cells and treatment responses using multicolor flow cytometry. The tumors, lymph nodes, and peripheral blood of gastric cancer patients who underwent gastrectomy following nivolumab treatment were collected, and nivolumab-binding PD-1
+
CD8
+
T cells in these tissue samples were characterized.
Results
Patients with a high frequency of CD103 among PD-1
+
CD8
+
T cells in peripheral blood 2 weeks after the start of treatment had significantly better progression-free survival than the low group (
P
= 0.032). This CD103
+
PD-1
+
CD8
+
T cell population mainly consisted of central memory T cells, showing the high expression of Ki-67 and few cytotoxic granules. In contrast, effector memory T cells were more frequently observed among CD103
+
PD-1
+
CD8
+
T cells in tumors, which implied a change in the differentiated status of central memory T cells in lymph nodes and peripheral blood to effector memory T cells in tumors during the treatment with ICIs.
Conclusions
A high frequency of CD103 among PD-1
+
CD8
+
T cells 2 weeks after nivolumab treatment in patients with advanced gastric cancer may be a useful biomarker for predicting the efficacy of anti-PD-1 therapy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35776160</pmid><doi>10.1007/s00262-022-03240-2</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-7004 |
| ispartof | Cancer Immunology, Immunotherapy, 2023-01, Vol.72 (1), p.169-181 |
| issn | 0340-7004 1432-0851 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10991138 |
| source | MEDLINE; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Apoptosis Biomarkers Biomarkers - metabolism Cancer Research CD103 antigen CD8 antigen CD8-Positive T-Lymphocytes Cell death Cytotoxicity Effector cells Flow cytometry Gastrectomy Gastric cancer Humans Immune checkpoint inhibitors Immunological memory Immunology Immunotherapy Lymph nodes Lymphatic system Lymphocytes Lymphocytes T Medicine Medicine & Public Health Memory cells Monoclonal antibodies Nivolumab - pharmacology Nivolumab - therapeutic use Oncology Original Original Article Patients PD-1 protein Peripheral blood Progression-Free Survival Stomach Neoplasms - pathology Targeted cancer therapy Tumors |
| title | The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T21%3A30%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20tissue-resident%20marker%20CD103%20on%20peripheral%20blood%20T%20cells%20predicts%20responses%20to%20anti-PD-1%20therapy%20in%20gastric%20cancer&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Nose,%20Yohei&rft.date=2023-01-01&rft.volume=72&rft.issue=1&rft.spage=169&rft.epage=181&rft.pages=169-181&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-022-03240-2&rft_dat=%3Cproquest_pubme%3E2760705826%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2760705826&rft_id=info:pmid/35776160&rfr_iscdi=true |